英国急性淋巴细胞白血病 2003 研究中 asparaginase 相关静脉血栓——重新暴露于 asparaginase 是可行且安全的。
Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
机构信息
Department of Haematology, Children's Hospital, The John Radcliffe, Oxford, UK.
出版信息
Br J Haematol. 2010 May;149(3):410-3. doi: 10.1111/j.1365-2141.2010.08132.x. Epub 2010 Mar 10.
We report the incidence and outcome of venous thrombosis (VT) in the UK acute lymphoblastic leukaemia (ALL) 2003 trial. VT occurred in 59/1824 (3.2%) patients recruited over 5 years with 90% occurring during a period of Asparagine depletion. Pegylated Escherichia Coli Asparaginase (Peg-ASP) 1000 units/m(2) was used throughout. Thirty-four children received further Peg-ASP, most with concurrent heparin prophylaxis. There were no episodes of bleeding or recurrent thrombosis. Optimal Asparagine depletion is central to success of modern regimes for treatment of ALL. This report confirms a significant risk of thrombosis with such therapy, but demonstrates that re-exposure to Asparaginase is feasible and safe.
我们报告了英国急性淋巴细胞白血病（ALL）2003 年试验中静脉血栓形成（VT）的发生率和结局。在 5 年的时间里，1824 名入组患者中有 59 名（3.2%）发生 VT，其中 90%发生在天冬酰胺耗竭期间。整个治疗过程中使用了 1000 单位/平方米的聚乙二醇化大肠埃希菌天冬酰胺酶（Peg-ASP）。34 名儿童接受了进一步的 Peg-ASP 治疗，大多数同时接受肝素预防。没有出血或复发血栓形成的病例。最佳的天冬酰胺耗竭是现代 ALL 治疗方案成功的关键。本报告证实了这种治疗方法存在显著的血栓形成风险，但也表明再次接触天冬酰胺酶是可行且安全的。
Zotero 插件